Receptor binding domain-IgG levels correlate with protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks.
BNT162b2 vaccine
COVID-19
SARS-CoV-2
antibody response
efficacy
neutralizing antibodies
nucleocapsid antigenemia
nursing homes
residents
symptoms
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
28
09
2021
received:
10
09
2021
accepted:
01
10
2021
pubmed:
16
10
2021
medline:
7
6
2022
entrez:
15
10
2021
Statut:
ppublish
Résumé
Limited information exists on nursing home (NH) residents regarding BNT162b2 vaccine efficacy in preventing SARS-CoV-2 and severe COVID-19, and its association with post-vaccine humoral response. 396 residents from seven NHs suffering a SARS-CoV-2 B.1.1.7 (VOC-α) outbreak at least 14 days after a vaccine campaign were repeatedly tested using SARS-CoV-2 real-time reverse-transcriptase polymerase chain reaction on nasopharyngeal swab test (RT-qPCR). SARS-CoV-2 receptor-binding domain (RBD) of the S1 subunit (RBD-IgG) was measured in all residents. Nucleocapsid antigenemia (N-Ag) was measured in RT-qPCR-positive residents and serum neutralizing antibodies in vaccinated residents from one NH. The incidence of positive RT-qPCR was lower in residents vaccinated by two doses (72/317; 22.7%) vs one dose (10/31; 32.3%) or non-vaccinated residents (21/48; 43.7%; p < .01). COVID-19-induced deaths were observed in 5 of the 48 non-vaccinated residents (10.4%), in 2 of the 31 who had received one dose (6.4%), and in 3 of the 317 (0.9%) who had received two doses (p = .0007). Severe symptoms were more common in infected non-vaccinated residents (10/21; 47.6%) than in infected vaccinated residents (15/72; 21.0%; p = .002). Higher levels of RBD-IgG (n = 325) were associated with a lower SARS-CoV-2 incidence. No in vitro serum neutralization activity was found for RBD-IgG levels below 1050 AU/ml. RBD-IgG levels were inversely associated with N-Ag levels, found as a risk factor of severe COVID-19. Two BNT162b2 doses are associated with a 48% reduction of SARS-CoV-2 incidence and a 91.3% reduction of death risk in residents from NHs facing a VOC-α outbreak. Post-vaccine RBD-IgG levels correlate with BNT162b2 protection against SARS-CoV-2 B.1.1.7.
Sections du résumé
BACKGROUND
Limited information exists on nursing home (NH) residents regarding BNT162b2 vaccine efficacy in preventing SARS-CoV-2 and severe COVID-19, and its association with post-vaccine humoral response.
METHODS
396 residents from seven NHs suffering a SARS-CoV-2 B.1.1.7 (VOC-α) outbreak at least 14 days after a vaccine campaign were repeatedly tested using SARS-CoV-2 real-time reverse-transcriptase polymerase chain reaction on nasopharyngeal swab test (RT-qPCR). SARS-CoV-2 receptor-binding domain (RBD) of the S1 subunit (RBD-IgG) was measured in all residents. Nucleocapsid antigenemia (N-Ag) was measured in RT-qPCR-positive residents and serum neutralizing antibodies in vaccinated residents from one NH.
RESULTS
The incidence of positive RT-qPCR was lower in residents vaccinated by two doses (72/317; 22.7%) vs one dose (10/31; 32.3%) or non-vaccinated residents (21/48; 43.7%; p < .01). COVID-19-induced deaths were observed in 5 of the 48 non-vaccinated residents (10.4%), in 2 of the 31 who had received one dose (6.4%), and in 3 of the 317 (0.9%) who had received two doses (p = .0007). Severe symptoms were more common in infected non-vaccinated residents (10/21; 47.6%) than in infected vaccinated residents (15/72; 21.0%; p = .002). Higher levels of RBD-IgG (n = 325) were associated with a lower SARS-CoV-2 incidence. No in vitro serum neutralization activity was found for RBD-IgG levels below 1050 AU/ml. RBD-IgG levels were inversely associated with N-Ag levels, found as a risk factor of severe COVID-19.
CONCLUSIONS
Two BNT162b2 doses are associated with a 48% reduction of SARS-CoV-2 incidence and a 91.3% reduction of death risk in residents from NHs facing a VOC-α outbreak. Post-vaccine RBD-IgG levels correlate with BNT162b2 protection against SARS-CoV-2 B.1.1.7.
Identifiants
pubmed: 34652831
doi: 10.1111/all.15142
pmc: PMC8652754
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1885-1894Informations de copyright
© 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Allergy. 2022 Jan;77(1):271-281
pubmed: 34286856
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
Allergy. 2022 Jun;77(6):1885-1894
pubmed: 34652831
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Nat Med. 2021 May;27(5):917-924
pubmed: 33772244
Clin Infect Dis. 2021 Dec 6;73(11):2145-2147
pubmed: 33825869
N Engl J Med. 2021 Jul 8;385(2):179-186
pubmed: 34161052
Science. 2021 Aug 6;373(6555):648-654
pubmed: 34210893
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166
pubmed: 34437519
Lancet Infect Dis. 2021 Nov;21(11):1529-1538
pubmed: 34174193
JAMA. 2021 Apr 15;:
pubmed: 33856406
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
J Clin Microbiol. 2021 Aug 18;59(9):e0028821
pubmed: 34260272
PLoS One. 2020 Aug 21;15(8):e0238160
pubmed: 32822430
N Engl J Med. 2020 May 21;382(21):2005-2011
pubmed: 32220208
Nat Commun. 2020 Oct 30;11(1):5493
pubmed: 33127906
J Nutr Health Aging. 2020;24(5):461-462
pubmed: 32346680
Eur J Clin Microbiol Infect Dis. 2021 Feb;40(2):269-277
pubmed: 32885293
Clin Infect Dis. 2022 Feb 11;74(3):517-520
pubmed: 33993228
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):639-643
pubmed: 33914720
J Nephrol. 2020 Aug;33(4):737-745
pubmed: 32602006
Clin Infect Dis. 2021 Sep 15;73(6):e1365-e1367
pubmed: 33768222
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Clin Infect Dis. 2021 Dec 6;73(11):2112-2115
pubmed: 33993265
Am J Transplant. 2021 Jun;21(6):2290-2297
pubmed: 34085760
Nat Commun. 2021 Feb 15;12(1):1018
pubmed: 33589636
Clin Infect Dis. 2022 Mar 1;74(4):707-710
pubmed: 34050731
Clin Microbiol Infect. 2020 Dec 8;:
pubmed: 33307227
J Am Med Dir Assoc. 2020 Jul;21(7):933-936
pubmed: 32674822
Eur Geriatr Med. 2020 Dec;11(6):899-913
pubmed: 33141405
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Eur Geriatr Med. 2020 Dec;11(6):1085-1088
pubmed: 33025500
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Nat Commun. 2021 May 25;12(1):3109
pubmed: 34035301